益生菌治疗肠易激综合征的疗效:系统评价与荟萃分析
该系统评价与荟萃分析检索截至2023年3月,纳入82项随机对照试验共10332例成人肠易激综合征患者,比较益生菌与安慰剂。部分益生菌或菌株组合可能对整体症状、腹痛或腹胀有益,但几乎所有分析的证据确定性按GRADE标准为低至极低。55项试验超过7000例患者中,益生菌组发生任何不良事件的风险未显著升高。
要点
- 部分益生菌或菌株组合可能对肠易激综合征有益,但证据确定性低至极低。
- 仅24项随机对照试验在所有领域为低偏倚风险。
- 55项试验超过7000例患者中,益生菌组任何不良事件风险未显著升高。
核心结论
- 部分益生菌组合或菌株可能对肠易激综合征有益,但几乎所有分析的疗效证据按GRADE标准为低至极低确定性。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、EMBASE和Cochrane对照试验注册库至2023年3月,纳入82项随机对照试验共10332例成人肠易激综合征患者,比较益生菌与安慰剂。
主要发现
- 整体症状方面,大肠杆菌菌株有中等确定性证据支持获益,乳杆菌菌株和植物乳杆菌299V为低确定性,复合益生菌、LacClean Gold S、Duolac 7s和芽孢杆菌菌株为极低确定性。
- 腹痛方面,酿酒酵母I-3856和双歧杆菌菌株有低确定性证据支持获益,复合益生菌、乳杆菌、酿酒酵母和芽孢杆菌菌株为极低确定性。
- 腹胀或腹部膨隆方面,复合益生菌和芽孢杆菌菌株为极低确定性证据支持获益。
- 55项试验超过7000例患者中,益生菌组发生任何不良事件的相对风险未显著升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 仅24项随机对照试验在所有领域为低偏倚风险。
- 几乎所有分析的疗效证据按GRADE标准为低至极低确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Some probiotics may be beneficial in irritable bowel syndrome (IBS), but differences in species and strains used, as well as endpoints reported, have hampered attempts to make specific recommendations as to which should be preferred. We updated our previous meta-analysis examining this issue. METHODS: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (up to March 2023). Randomized controlled trials (RCTs) recruiting adults with IBS, comparing probiotics with placebo were eligible. Dichotomous symptom data were pooled to obtain a relative risk of global symptoms, abdominal pain, or abdominal bloating or distension persisting after therapy, with a 95% confidence interval (CI). Continuous data were pooled using a standardized mean difference with a 95% CI. Adverse events data were also pooled. RESULTS: We identified 82 eligible trials, containing 10,332 patients. Only 24 RCTs were at low risk of bias across all domains. For global symptoms, there was moderate certainty in the evidence for a benefit of Escherichia strains, low certainty for Lactobacillus strains and Lactobacillus plantarum 299V, and very low certainty for combination probiotics, LacClean Gold S, Duolac 7s, and Bacillus strains. For abdominal pain, there was low certainty in the evidence for a benefit of Saccharomyces cerevisae I-3856 and Bifidobacterium strains, and very low certainty for combination probiotics, Lactobacillus, Saccharomyces, and Bacillus strains. For abdominal bloating or distension there was very low certainty in the evidence for a benefit of combination probiotics and Bacillus strains. The relative risk of experiencing any adverse event, in 55 trials, including more than 7000 patients, was not significantly higher with probiotics. CONCLUSIONS: Some combinations of probiotics or strains may be beneficial in IBS. However, certainty in the evidence for efficacy by GRADE criteria was low to very low across almost all of our analyses.
引用
- Goodoory VC, Khasawneh M, Black CJ, et al. Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. Gastroenterology. 2023. PMID: 37541528. doi:10.1053/j.gastro.2023.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。